In the years to come, Bavarian Nordic foresees that more commercially minded-business taking the lead over the sort of ...

Vimkunya™ (chikungunya vaccine, recombinant) is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years ...

Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the second company in the US to market a vaccine for the tropical disease.

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...

Bavarian Nordic CEO Paul Chaplin warns US pharma reshoring could take 5-10 years, citing tech transfer complexities. Company ...

Bavarian Nordic AS (BVNKF) reports robust revenue and EBITDA growth, while navigating manufacturing challenges and market ...

Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the ...

About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic 2024 Annual Report Conference call. At this time all participants are in a listen-only mode. After the speakers' presentation ...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline ...